Pharmaceuticals

The chart shows the growth of an initial investment of $10,000 in Pharmaceuticals, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

As of Apr 2, 2026, the Pharmaceuticals returned 11.48% Year-To-Date and 11.11% of annualized return in the last 10 years.

Based on dividend-adjusted daily data since Jan 3, 2013, Pharmaceuticals's average daily return is +0.05%, while the average monthly return is +1.00%. At this rate, your investment would double in approximately 5.8 years.

Historically, 61% of months were positive and 39% were negative. The best month was Nov 2020 with a return of +12.5%, while the worst month was Aug 2022 at -8.8%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 4 months.

On a daily basis, Pharmaceuticals closed higher 53% of trading days. The best single day was Mar 13, 2020 with a return of +6.6%, while the worst single day was Mar 16, 2020 at -8.6%.

Pharmaceuticals has an annualized alpha of 5.03%, beta of 0.58, and R² of 0.38 versus S&P 500 Index. Calculated based on daily prices since January 03, 2013.

• This portfolio participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (77.86%) than losses (72.45%) — typical of diversified or defensive assets.
• Beta of 0.58 may look defensive, but with R² of 0.38 this portfolio is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this portfolio's risk.
• R² of 0.38 means the benchmark explains less than half of this portfolio's behavior — treat beta with caution or consider switching to a more representative benchmark.

Pharmaceuticals has an expense ratio of 0.00%, meaning no management fees are charged. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

Pharmaceuticals ranks 72 for risk / return — better than 72% of portfolios on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Pharmaceuticals Sharpe ratios as of Apr 2, 2026 (values are recalculated daily):

• 1-Year: 1.68
• 5-Year: 0.75
• 10-Year: 0.68
• All Time: 0.73

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 1.00 to 1.69, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of Pharmaceuticals compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

Pharmaceuticals provided a 3.68% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Pharmaceuticals. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pharmaceuticals was 27.23%, occurring on Mar 23, 2020. Recovery took 175 trading sessions.

The current Pharmaceuticals drawdown is 2.24%.

The chart below shows the rolling one-month volatility.